Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma
The Journal of Allergy and Clinical Immunology: In Practice · 2023-06 · 11 (6) · 1805-1813
DOI: 10.1016/j.jaip.2023.02.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-06. Verfasst von Eugene R Bleecker und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Arizona College of Medicine, Tucson, Ariz. Electronic address: erbleecker@uarizona.edu. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
BACKGROUND: The stability and variability of blood eosinophil counts (BECs) to phenotype patients with severe asthma is not fully understood. OBJECTIVE: This post hoc, longitudinal, pooled analysis of placebo-arm patients from 2 phase 3 studies evaluated the clinical implications of BEC stability and variability in moderate-to-severe asthma. METHODS: This analysis included patients from SIROCCO and CALIMA who received maintenance medium- to high-dosage inhaled corticosteroids plus long-acting β2-agonists; 2:1 patients with BECs of 300 cells/μL or higher and less than 300 cells/μL were enrolled. The BECs were measured 6 times over 1 year in a centralized laboratory. Exacerbations, lung function, and Asthma Control Questionnaire 6 scores were documented across patients grouped by BEC (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Arizona College of Medicine, Tucson, Ariz. Electronic address: erbleecker@uarizona.edu.
- Department of Medicine, University of Arizona College of Medicine, Tucson, Ariz.
- Arizona Statistical Consulting, University of Arizona College of Public Health, Tucson, Ariz.
- Late-stage Respiratory & Immunology, AstraZeneca, Gaithersburg, Md.
- BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.
- Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
Förderung
- AstraZeneca
Zitieren
APA
Bleecker, E. R., Meyers, D. A., Billheimer, D., Li, H., Newbold, P., Kwiatek, J., Hirsch, I., Katial, R., & Li, X. (2023). Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice, 11(6), 1805-1813. https://doi.org/10.1016/j.jaip.2023.02.020
Vancouver
Bleecker ER, Meyers DA, Billheimer D, Li H, Newbold P, Kwiatek J, et al. Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(6):1805-1813. doi:10.1016/j.jaip.2023.02.020
BibTeX
@article{Bleecker2023,
author = {Bleecker, Eugene R and Meyers, Deborah A and Billheimer, Dean and Li, Huashi and Newbold, Paul and Kwiatek, Justin and Hirsch, Ian and Katial, Rohit and Li, Xingnan},
title = {Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2023},
volume = {11},
number = {6},
pages = {1805--1813},
doi = {10.1016/j.jaip.2023.02.020}
}
EUVIMED